Profile
| Metric | Value |
|---|---|
| Full Name | Illumina, Inc. |
| Ticker | NASDAQ: ILMN |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | illumina.com |
| Employees | 8,970 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $145.83 | |
| Price, 1D Change | -2.87% | |
| Market Cap | $22B | |
| - | ||
| PE Ratio | 32.67 | |
| Beta | 1.11 | |
| Revenue | $4B | |
| Revenue, 1Y Change | -2.93% | |
| EPS | -$7.69 | |
| EPS, 1Y Change | -4.68% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 2:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$7.69 | |
| EPS Estimate | $4.71 | |
| EPS Est. Change | +161.21% | |
| Revenue | $4.37B | |
| Revenue Estimate | $4.29B | |
| Revenue Est. Change | -1.99% | |
| Current Price | $145.83 | |
| Price Target | - | $130.00 |
| Price Tgt. Change | - | -10.86% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $0.73 | -$7.35 | -1,106.59% | |
| $4.13 | -$7.69 | -286.30% | |
| $4.71 | N/A | +161.21% | |
| $5.05 | N/A | +165.60% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $4.48B | $4.50B | +0.63% | |
| $4.34B | $4.37B | +0.73% | |
| $4.29B | N/A | -1.99% | |
| $4.38B | N/A | +0.22% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +4.40% | |
| Price, 3Y | -25.74% | |
| Market Cap, 1Y | +0.33% | |
| Market Cap, 3Y | -28.18% | |
| Revenue, 1Y | -2.93% | |
| Revenue, 3Y | -3.40% | |
| EPS, 1Y | -4.68% | |
| EPS, 3Y | -252.42% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $145.83 | |
| SMA 200 | $100.12 | |
| SMA 200 vs Price | -31.35% | |
| SMA 50 | $127.52 | |
| SMA 50 vs Price | -12.55% | |
| Beta | 1.11 | |
| ATR | $4.18 | |
| 14-Day RSI | 66.40 | |
| 10-Day Volatility | 41.24% | |
| 1-Year Volatility | 49.72% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $4.37B | |
| EPS | -$7.69 | |
| Gross Profit | $2.86B | |
| Gross Margin | 65.46% | |
| Operating Profit | $400.00M | |
| Operating Margin | 9.15% | |
| Net Income | -$1.22B | |
| Net Margin | -27.97% | |
| EBITDA | $754.00M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 1.10 | |
| Current Ratio | 1.78 | |
| Quick Ratio | 1.42 | |
| - | ||
| F-Score | 8 | |
| Altman Z-Score | 4.26 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 32.67 | |
| PS Ratio | 5.20 | |
| PB Ratio | 9.36 | |
| EV/EBITDA | 21.10 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $2.37B | |
| Cash & Equivalents | $1.22B | |
| Total Assets | $6.30B | |
| Current Assets | $2.75B | |
| Total Liabilities | $3.93B | |
| Current Liabilities | $1.55B | |
| Total Debt | $2.62B | |
| Short Term Debt | $578.00M | |
| Accounts Payable | $221.00M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $5.60B | |
| Operating Expenses | $2.46B | |
| Cost Of Goods Sold | $1.51B | |
| SG&A | $0.00 | |
| D&A | $354.00M | |
| Interest Expense | $0.00 | |
| Income Tax | $44.00M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $837.00M | |
| CFI | -$178.00M | |
| CFF | -$570.00M | |
| Capex | $209.00M | |
| Free Cash Flow | $628.00M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Guggenheim | → | |
| Canaccord Genuity | → | |
| JP Morgan | → | |
| Barclays | → | |
| UBS | → | |
| TD Cowen | → | |
| JP Morgan | → | |
| Evercore ISI Group | → | |
| Canaccord Genuity | → | |
| Barclays | → |
Analyst sentiment
Institutional ownership
Screeners with ILMN
Data Sources & References
- ILMN Official Website www.illumina.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1110803/000111080325000073/0001110803-25-000073-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1110803/000111080325000019/0001110803-25-000019-index.htm
- ILMN Profile on Yahoo Finance finance.yahoo.com/quote/ILMN
- ILMN Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/ilmn
FAQ
What is the ticker symbol for Illumina, Inc.?
The ticker symbol for Illumina, Inc. is NASDAQ:ILMN
Does Illumina, Inc. pay dividends?
No, Illumina, Inc. does not pay dividends
What sector is Illumina, Inc. in?
Illumina, Inc. is in the Healthcare sector
What industry is Illumina, Inc. in?
Illumina, Inc. is in the Diagnostics & Research industry
What country is Illumina, Inc. based in?
Illumina, Inc. is headquartered in United States
When did Illumina, Inc. go public?
Illumina, Inc. initial public offering (IPO) was on July 28, 2000
Is Illumina, Inc. in the S&P 500?
No, Illumina, Inc. is not included in the S&P 500 index
Is Illumina, Inc. in the NASDAQ 100?
No, Illumina, Inc. is not included in the NASDAQ 100 index
Is Illumina, Inc. in the Dow Jones?
No, Illumina, Inc. is not included in the Dow Jones index
When was Illumina, Inc. last earnings report?
Illumina, Inc.'s most recent earnings report was on October 30, 2025
When does Illumina, Inc. report earnings?
The next expected earnings date for Illumina, Inc. is February 5, 2026